Toshiba showcases imaging systems at RSNA conference

Toshiba has a lot of news coming from the Radiological Society of North America annual meeting in Chicago this week as it touts the advantages of its technologies.

At the conference, the company showed off its Aplio 300 and 500 ultrasound systems. The Aplio 300 system is designed to offer exceptional image quality in a smaller, versatile platform for routine ultrasound exams, according to the company. Meanwhile, the Aplio 500 comes with optional Fly Thru and Smart Fusion features, which, respectively, allow clinicians to explore the interiors of ducts and vessels and to view CT and ultrasound images side-by-side on a single screen.

The company also showcased its Aquilion Prime CT, which it says allows for extremely accurate MPR and 3-D-rendered images. The system, which is awaiting FDA clearance, is designed to produce high quality clinical images with the least amount of radiation exposure, according to a release.

Toshiba also touted the benefits of its Vantage Titan 3T MR, which is equipped with advanced multiphase RF transmission technology that reduces dielectric shading artifacts.

"Vantage Titan 3T MR is the industry's first 3T MR system that enables hospitals to use a single MR system to address all their clinical needs," said Stuart Clarkson, director of Toshiba's MR business unit. "This system is an example of our commitment to developing technology to solve patient and clinical challenges facing the 3T market today."

- check out Toshiba's release on the Aplio 300 system
- get more on Aplio 500
- read the Aquilion release
- and see the Vintage Titan release

ALSO: Toshiba has announced the introduction of the Vantage Titan 1.5T MR series. In addition to the current 16-channel system, Toshiba will offer 8-channel (works-in-progress) and 32-channel (WIP) systems. Toshiba release

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.